- Home
- YI vs IPSC Comparison
YI vs IPSC Comparison
Compare YI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- IPSC
- Stock Information
- Founded
- YI 2010
- IPSC 2019
- Country
- YI China
- IPSC United States
- Employees
- YI N/A
- IPSC N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- YI Consumer Staples
- IPSC Health Care
- Exchange
- YI Nasdaq
- IPSC Nasdaq
- Market Cap
- YI 68.5M
- IPSC 77.3M
- IPO Year
- YI N/A
- IPSC 2021
- Fundamental
- Price
- YI $8.26
- IPSC $0.73
- Analyst Decision
- YI
- IPSC Strong Buy
- Analyst Count
- YI 0
- IPSC 5
- Target Price
- YI N/A
- IPSC $11.00
- AVG Volume (30 Days)
- YI 46.0K
- IPSC 511.6K
- Earning Date
- YI 03-20-2025
- IPSC 03-13-2025
- Dividend Yield
- YI N/A
- IPSC N/A
- EPS Growth
- YI N/A
- IPSC N/A
- EPS
- YI N/A
- IPSC N/A
- Revenue
- YI $2,090,255,896.00
- IPSC $2,684,000.00
- Revenue This Year
- YI $61.85
- IPSC $230.60
- Revenue Next Year
- YI N/A
- IPSC $31.83
- P/E Ratio
- YI N/A
- IPSC N/A
- Revenue Growth
- YI N/A
- IPSC 7.88
- 52 Week Low
- YI $0.41
- IPSC $0.68
- 52 Week High
- YI $8.81
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- YI 87.81
- IPSC 34.24
- Support Level
- YI $6.88
- IPSC $0.72
- Resistance Level
- YI $8.44
- IPSC $0.82
- Average True Range (ATR)
- YI 0.50
- IPSC 0.06
- MACD
- YI -0.01
- IPSC 0.01
- Stochastic Oscillator
- YI 78.83
- IPSC 40.50
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.